

DQSRPVQPFLNLTTPRKPRPPRRRQRRKKRG-NH2



# **Data Sheet**

Product Name: D-JNKI-1
Cat. No.: CS-5324

CAS No.: 1445179-97-4

Molecular Formula: C164H286N66O40

Molecular Weight: 3822.44

Target: JNK

Pathway: MAPK/ERK Pathway

**Solubility:**  $H2O : \geq 50 \text{ mg/mL } (13.08 \text{ mM})$ 

# **BIOLOGICAL ACTIVITY:**

D-JNKI-1 is a highly potent and cell-permeable peptide inhibitor of **JNK. In Vitro:** D-JNKI-1 (1  $\mu$ M-1 mM) treatment prevents apoptosis and loss of neomycin-exposed hair cells<sup>[1]</sup>. **In Vivo:** D-JNKI-1 (10  $\mu$ M) prevents nearly all hair cell death and permanent hearing loss induced by neomycin ototoxicity in the scala tympani of the guinea pig cochlea. Local delivery of D-JNKI-1 also prevents acoustic trauma-induced permanent hearing loss in a dose-dependent manner<sup>[1]</sup>. D-JNKI-1 (0.3 mg/kg, i.p.) reverses these pathological events in the brain mitochondria of the rat and almost completely abolishes cytochrome c release and PARP cleavage<sup>[2]</sup>. D-JNKI-1 (1  $\mu$ g/kg, s.c.) results in a significant decrease in the disease activity index, and reduces the expression of CD4+ and CD8+ cells in mice<sup>[3]</sup>.

# PROTOCOL (Extracted from published papers and Only for reference)

Animal Administration: D-JNKI-1 is dissolved in a 0.9% sodium chloride solution. [3]D-JNKI-1 is dissolved in a 0.9% sodium chloride solution for subcutaneous application. Each group (the 1.0% DSS group and the 1.5% DSS group) is randomly subdivided into an intervention group (n = 15) and a control group (n = 15). The mice in the intervention group receive three subcutaneous nuchal administrations of 1  $\mu$ g/kg D-JNKI-1 on days 2, 12, and 22. The mice in the control group receive physiological saline subcutaneously as a negative control at the same time points in a comparable stress situation.

### References:

- [1]. Wang J, et al. A peptide inhibitor of c-Jun N-terminal kinase protects against both aminoglycoside and acoustic trauma-induced auditory hair cell death and hearing loss. J Neurosci. 2003 Sep 17;23(24):8596-607.
- [2]. Zhao Y, et al. The JNK inhibitor D-JNKI-1 blocks apoptotic JNK signaling in brain mitochondria. Mol Cell Neurosci. 2012 Mar;49(3):300-10.
- [3]. Kersting S, et al. The impact of JNK inhibitor D-JNKI-1 in a murine model of chronic colitis induced by dextran sulfate sodium. J Inflamm Res. 2013 May 3:6:71-81.
- [4]. Wang C, et al. Wu-tou decoction attenuates neuropathic pain via suppressing spinal astrocytic IL-1R1/TRAF6/JNK signaling. Oncotarget. 2017 Oct 6:8(54):92864-92879.

### **CAIndexNames**:

DQSRPVQPFLNLTTPRKPRPPRRRQRRKKRG

Page 1 of 2 www.ChemScene.com

# **SMILES:** [DQSRPVQPFLNLTTPRKPRPPRRRQRRKKRG-NH2] Caution: Product has not been fully validated for medical applications. For research use only. Tel: 732-484-9848 Fax: 888-484-5008 E-mail: sales@ChemScene.com Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.ChemScene.com